Cadent Therapeutics: Results from Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor – CBI
Homepage /  Press Release /  Cadent Therapeutics: Results from Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor

Press Release

Cadent Therapeutics: Results from Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor